PVC Risk Management Planning 2 — Questions and Answers
Question 1: Which ICH guideline specifically addresses the development and implementation of Risk Management Plans (RMPs)?
- ICH E2A
- ICH E2E (Correct answer)
- ICH E2C
- ICH E2F
Correct answer: ICH E2E
ICH E2E (Pharmacovigilance Planning) provides guidance on pharmacovigilance planning including the development of RMPs.
Question 2: What is the primary purpose of a Pharmacovigilance System Master File (PSMF) in relation to risk management?
- To document all adverse events reported to the MAH
- To describe the pharmacovigilance system and demonstrate its adequacy (Correct answer)
- To list all contraindications for a medicinal product
- To outline the marketing strategy for a new drug
Correct answer: To describe the pharmacovigilance system and demonstrate its adequacy
The PSMF describes the pharmacovigilance system used by the MAH and demonstrates it meets regulatory requirements, supporting overall risk management.
Question 3: In an EU Risk Management Plan, which module specifically addresses the 'missing information' category of safety concerns?
- Module SI — Safety Specification (Correct answer)
- Module SII — Pharmacovigilance Plan
- Module SVII — Risk Minimisation Measures
- Module SV — Risk Identification and Characterisation
Correct answer: Module SI — Safety Specification
Module SI of the EU RMP Safety Specification includes the 'Missing Information' section that identifies gaps in safety knowledge.
Question 4: A company identifies a new signal for a product already on the market. Which action within risk management planning is MOST immediately required?
- Automatically withdraw the product from the market
- Evaluate the signal and determine if RMP update is warranted (Correct answer)
- Publish a press release about the new safety concern
- Increase the frequency of PSUR submissions only
Correct answer: Evaluate the signal and determine if RMP update is warranted
Signal evaluation is required first; if the signal is validated and changes the benefit-risk profile, the RMP must be updated accordingly.
Question 5: What distinguishes an 'important identified risk' from an 'important potential risk' in pharmacovigilance?
- Identified risks are only those listed in the package insert
- Identified risks have sufficient evidence of a causal association; potential risks have limited evidence (Correct answer)
- Potential risks are theoretical only and need not be monitored
- Identified risks always require urgent safety restriction measures
Correct answer: Identified risks have sufficient evidence of a causal association; potential risks have limited evidence
Important identified risks have established evidence of causal association, while important potential risks are suspected but lack conclusive evidence.
Question 6: Which tool is considered an ADDITIONAL risk minimization measure (aRMM) as opposed to a routine one?
- Summary of Product Characteristics (SmPC)
- Patient Information Leaflet (PIL)
- Controlled distribution program (Correct answer)
- Labeling updates
Correct answer: Controlled distribution program
Controlled distribution programs restrict prescribing or dispensing to specific settings or patients, making them additional rather than routine measures.
Question 7: Under EU GVP Module V, how often must a MAH submit an RMP update in the absence of a specific regulatory request?
- Annually for the first 2 years after approval
- Only when requested by the EMA
- When a new safety concern is identified or when the benefit-risk profile changes (Correct answer)
- Every 6 months throughout the product's lifecycle
Correct answer: When a new safety concern is identified or when the benefit-risk profile changes
RMP updates are triggered by new safety concerns, changes in benefit-risk profile, or at defined lifecycle milestones, not on a fixed annual schedule.
PVC Risk Management Planning 2
Which ICH guideline specifically addresses the development and implementation of Risk Management Plans (RMPs)?